Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis sy… Read more
Market Cap & Net Worth: Wuhan Thalys Med Tech Co Ltd (603716)
Wuhan Thalys Med Tech Co Ltd (SHG:603716) has a market capitalization of $653.75 Million (CN¥4.80 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #9877 globally and #2100 in its home market, demonstrating a -4.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Thalys Med Tech Co Ltd's stock price CN¥22.82 by its total outstanding shares 210199126 (210.20 Million).
Wuhan Thalys Med Tech Co Ltd Market Cap History: 2016 to 2026
Wuhan Thalys Med Tech Co Ltd's market capitalization history from 2016 to 2026. Data shows growth from $1.02 Billion to $653.75 Million (8.12% CAGR).
Wuhan Thalys Med Tech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Thalys Med Tech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.11x
Wuhan Thalys Med Tech Co Ltd's market cap is 0.11 times its annual revenue
0.69x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.02 Billion | $627.33 Million | $68.92 Million | 1.63x | 14.83x |
| 2017 | $563.80 Million | $920.52 Million | $93.85 Million | 0.61x | 6.01x |
| 2018 | $542.35 Million | $1.32 Billion | $94.16 Million | 0.41x | 5.76x |
| 2019 | $481.36 Million | $1.83 Billion | $110.42 Million | 0.26x | 4.36x |
| 2020 | $471.84 Million | $2.13 Billion | $82.03 Million | 0.22x | 5.75x |
| 2021 | $412.25 Million | $2.60 Billion | -$38.38 Million | 0.16x | N/A |
| 2022 | $316.28 Million | $2.31 Billion | -$191.26 Million | 0.14x | N/A |
| 2023 | $317.71 Million | $2.01 Billion | -$158.57 Million | 0.16x | N/A |
| 2024 | $206.84 Million | $1.81 Billion | -$209.24 Million | 0.11x | N/A |
Competitor Companies of 603716 by Market Capitalization
Companies near Wuhan Thalys Med Tech Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Wuhan Thalys Med Tech Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
Wuhan Thalys Med Tech Co Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Wuhan Thalys Med Tech Co Ltd's market cap moved from $1.02 Billion to $ 653.75 Million, with a yearly change of 8.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥653.75 Million | +11.05% |
| 2025 | CN¥588.72 Million | +184.63% |
| 2024 | CN¥206.84 Million | -34.90% |
| 2023 | CN¥317.71 Million | +0.45% |
| 2022 | CN¥316.28 Million | -23.28% |
| 2021 | CN¥412.25 Million | -12.63% |
| 2020 | CN¥471.84 Million | -1.98% |
| 2019 | CN¥481.36 Million | -11.25% |
| 2018 | CN¥542.35 Million | -3.80% |
| 2017 | CN¥563.80 Million | -44.85% |
| 2016 | CN¥1.02 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Wuhan Thalys Med Tech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $653.75 Million USD |
| MoneyControl | $653.75 Million USD |
| MarketWatch | $653.75 Million USD |
| marketcap.company | $653.75 Million USD |
| Reuters | $653.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.